Asthma and COPD Drugs Market

Asthma and COPD Drugs Market Insights

The global Asthma and COPD Drugs Market Size was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64% from 2021 to 2030. Asthma is a non-communicable, chronic inflammatory lung disorder of the airways. Airways hyper-responsiveness leads to recurrent episodes of wheezing, breathlessness, chest tightness, and cough. Asthma is largely reversible as compared to other obstructive lung diseases. Allergy is the strongest risk factor for asthma. Moreover, asthma can be triggered by exposure of irritants, exercise, β blockers, cold air, animals, and dust. The chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. COPD includes emphysema; a complex lung disease characterized by damage to alveoli and chronic bronchitis; a chronic inflammation to lower respiratory track. Tobacco smoking is the major cause for COPD. In addition, passive smoking, occupational exposure, and ambient air pollution are risk factors for COPD.

The asthma and COPD can be diagnosed with physical examination and several tests such as X-ray, sputum eosinophils, and nitric oxide test. Asthma and COPD can be treated with inhaled corticosteroids, leukotriene modifiers, and theophylline. However, acute respiratory attack can be controlled with the short-acting beta agonists and anticholinergic drugs.

The growth of the global Asthma and COPD Drugs Market is majorly driven by the increase in prevalence of asthma and COPD. For instance, according to world health organisation (WHO), asthma affected an estimated 262 million people and caused 46,1000 deaths in 2019. Furthermore, the rise in number of COPD patients contributes to the growth of market. For instance, according to American Lung Organization, 99 million adults had chronic bronchitis and 2 million adults had emphysema in U.S. in 2018. 

Moreover, advancement in respiratory diseases therapy and new product launches in the global Asthma and Chronic Obstructive Pulmonary Disease Drugs Market are anticipated to contribute toward the growth of the market. For instance, in December 2020, AstraZenca, a leading manufacturer of pharmaceuticals, received EU Approval for ‘Trixeo Aerosphere’ for maintenance treatment of COPD. However, high cost of associated asthma treatment restricts the market growth during the forecast period.

Global Asthma And Copd Drugs Market Segmentation 

The Asthma and COPD Drugs Market is segmented on the basis of disease, medication class, and region. By disease, the market is mainly categorized into asthma and COPD.
By medication class, it is categorized in combination drugs, inhaled corticosteroids (ics), short acting beta agonists (saba), long acting beta agonists (laba), leukotriene antagonists (lta), anticholinergics, and others.

By region, the Asthma and COPD Drugs Market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).

Segment Review

Depending on disease, the asthma segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in asthma patients. However, the COPD segment is expected to witness considerable growth during the forecast period, owing to advancements in COPD therapy. 

Depending on medication class, the combination drugs segment was the major contributor in 2020 and is expected to maintain its lead during the forecast period, owing to reliability of combination therapy. However, the inhaled corticosteroids segment is expected to witness considerable growth during the forecast period, due to advancement in therapy.

Depending on the region, North America garnered the major share in the Asthma and COPD Drugs Market in 2020, and is expected to dominate the global market during the forecast period, owing to the rise in prevalence of asthma, presence of key players for manufacturing, tobacco smoking habit, and well-established infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 5.81% from 2021 to 2030, owing to an increase in the number of hospitals and high population.

Key Benefits For Stakeholders

• The report provides an in-depth analysis of the global Asthma and COPD Drugs Market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers Asthma and Chronic Obstructive Pulmonary Disease Drugs Market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Asthma and COPD Drugs Market growth.

 Asthma and COPD Drugs Market Report Highlights